Antiparkinsonian Drugs

Classification

Precursor: levodopa(+carbidopa/benserazide always). Dopamine agonists: pramipexole/ropinirole(non-ergot) · bromocriptine/cabergoline(ergot). MAO-B inhibitors: selegiline, rasagiline. COMT inhibitors: entacapone, tolcapone. Anticholinergics: trihexyphenidyl, benztropine. Amantadine(separate mechanism). Decarboxylase inhibitors: carbidopa, benserazide(NEVER alone).

Pathophysiology

Substantia nigra pars compacta dopaminergic neuron loss → dopamine deficiency RELATIVE TO intact cholinergic tone in striatum = core imbalance. Two correction directions: ↑dopaminergic signalling(most drugs) OR ↓relatively-excess cholinergic signalling(anticholinergics).

Mechanism

Levodopa: dopamine precursor, CROSSES BBB(via LNAA transporter) unlike dopamine itself → decarboxylated to dopamine in CNS. ALWAYS +peripheral decarboxylase inhibitor(carbidopa/benserazide, doesn’t cross BBB, blocks ONLY peripheral conversion) → ↑fraction reaching CNS(lower dose needed) + ↓peripheral dopamine SE(esp N/V — peripheral dopamine stimulates CTZ, outside BBB) + ↓cardiovascular effects. Most effective symptomatic Rx, BUT chronic use → motor fluctuations(“wearing-off”) + dyskinesias(pulsatile non-physiological receptor stimulation) → rationale for delaying initiation in younger patients.

Dopamine agonists: direct striatal receptor action, no presynaptic conversion needed. Early disease monotherapy(younger pts, delays levodopa complications) or later adjunct. Ergot agents(bromocriptine, cabergoline): cardiac valvulopathy + retroperitoneal/pulmonary fibrosis(5-HT2B agonism, off-target) → non-ergot(pramipexole, ropinirole) preferred routinely.

MAO-B inhibitors: selective MAO-B(dopamine-predominant breakdown isoform, vs A=NA/5-HT) → avoids tyramine reaction AT STANDARD DOSE(lost at high dose). Monotherapy early disease(mild effect, debated neuroprotection) or adjunct(↓wearing-off).

COMT inhibitors: block COMT(peripheral levodopa degradation, separate pathway from decarboxylation already blocked by carbidopa) → ADJUNCT ONLY(no independent effect) → extends levodopa t½, smooths fluctuations. Tolcapone = hepatotoxicity risk(LFT monitoring) — distinguishes from entacapone.

Anticholinergics: block muscarinic receptors → ↓relative cholinergic excess. Best for TREMOR specifically(less effect on bradykinesia/rigidity). More useful in YOUNGER patients or DRUG-INDUCED parkinsonism than typical older-onset PD(poor anticholinergic SE tolerance in elderly).

Amantadine: multifactorial(↑dopamine release, ↓reuptake, NMDA antagonism) — NMDA action explains SEPARATE use for levodopa-induced DYSKINESIAS specifically(distinct from parkinsonian symptom use). Modest effect, early/mild disease or dyskinesia adjunct.

Adverse Effects

Levodopa: N/V+postural hypotension(peripheral, ↓but not eliminated by carbidopa) · psychiatric(hallucinations/confusion, esp elderly/cognitive impairment) · motor fluctuations+dyskinesias(chronic use).

Dopamine agonists: MORE pronounced psychiatric/hallucinatory effects than levodopa at equivalent benefit + IMPULSE CONTROL DISORDERS(pathological gambling, hypersexuality, compulsive shopping/eating — mesolimbic reward circuitry stimulation, NOT shared to same degree by levodopa). Ergot: valvulopathy/fibrosis.

MAO-B inhibitors: well tolerated at selective dose; insomnia(selegiline amphetamine metabolites); tyramine risk if selectivity lost(high dose/combinations).

Anticholinergics: standard antimuscarinic(dry mouth, blurred vision, urinary retention, constipation, confusion — esp problematic elderly, generally avoided).

Drug-Induced Parkinsonism

Classic cause: typical antipsychotics(D2 blockade) → reproduces dopamine-deficient STATE pharmacologically(blocked receptors, not lost neurons) but functionally similar net striatal effect. Management: reduce/switch offending drug. Anticholinergics USEFUL here(corrects relative cholinergic excess directly); levodopa generally INEFFECTIVE(no dopamine shortage to replace — receptors just blocked).

Clinical Relevance

Dopamine/acetylcholine balance framework organizes the whole drug list: dopamine-boosting strategies(precursor, agonist, ↓breakdown via 2 independent enzymes) address one side; anticholinergics address the other directly. SAME framework explains why anticholinergics(not levodopa) are rational in drug-induced parkinsonism — problem = excess receptor blockade, not dopamine shortfall.

Classification

1. Dopamine precursor: levodopa (always with a peripheral decarboxylase inhibitor — carbidopa or benserazide)
2. Dopamine agonists: pramipexole, ropinirole (non-ergot), bromocriptine, cabergoline (ergot-derived)
3. MAO-B inhibitors: selegiline, rasagiline
4. COMT inhibitors: entacapone, tolcapone
5. Anticholinergics: trihexyphenidyl, benztropine
6. Amantadine: originally an antiviral, antiparkinsonian by a separate mechanism
7. Dopa decarboxylase inhibitors: carbidopa, benserazide (never used alone — always combined with levodopa)

Pathophysiological Basis

Parkinson’s disease results from degeneration of dopaminergic neurons in the substantia nigra pars compacta, projecting to the striatum — the resulting dopamine deficiency relative to intact cholinergic (acetylcholine) tone in the striatum is the core biochemical imbalance every drug class in this topic addresses, from one of two directions: increase dopaminergic signalling (levodopa, dopamine agonists, MAO-B/COMT inhibitors, amantadine) or reduce the now-relatively-excessive cholinergic signalling (anticholinergics) — restoring the dopamine/acetylcholine balance rather than dopamine level in isolation.

Mechanism of Action

Levodopa: the metabolic precursor of dopamine, given because dopamine itself cannot cross the blood-brain barrier while levodopa (via the large neutral amino acid transporter) can — once inside the CNS, it is decarboxylated to dopamine by dopa decarboxylase, replenishing striatal dopamine. Always co-administered with a peripheral decarboxylase inhibitor (carbidopa/benserazide), which cannot itself cross the blood-brain barrier and so only blocks peripheral conversion of levodopa to dopamine — this peripheral-only blockade increases the fraction of an oral dose reaching the CNS intact (allowing a substantially lower levodopa dose for the same central effect) and specifically reduces peripheral dopamine-mediated adverse effects, above all nausea/vomiting (peripheral dopamine strongly stimulates the chemoreceptor trigger zone, which lies outside the blood-brain barrier and is therefore exposed to peripherally-generated dopamine) and cardiovascular effects. Levodopa remains the most effective symptomatic therapy available, but chronic use is limited by motor fluctuations (“wearing-off” effect as disease progresses and the therapeutic window narrows) and dyskinesias (involuntary movements from pulsatile, non-physiological striatal dopamine receptor stimulation) — the rationale behind delaying levodopa initiation in younger patients where feasible, and behind the drug classes below that provide alternative or adjunct dopaminergic support.

Dopamine agonists: act directly on striatal dopamine receptors, independent of any need for presynaptic conversion — useful as monotherapy in early disease (particularly in younger patients, to delay levodopa-associated motor complications) or as levodopa adjuncts in later disease. Ergot-derived agents (bromocriptine, cabergoline) carry a distinctive risk of cardiac valvulopathy and retroperitoneal/pulmonary fibrosis (from 5-HT2B receptor agonism, an off-target ergot effect), which has shifted preference toward the non-ergot agents (pramipexole, ropinirole) for routine use.

MAO-B inhibitors (selegiline, rasagiline): selectively inhibit monoamine oxidase type B, the isoform predominantly responsible for dopamine (rather than noradrenaline/serotonin) breakdown in the CNS — selectivity for the B isoform at standard doses avoids the tyramine (“cheese reaction”) risk associated with non-selective MAO inhibition, though selectivity is lost at higher doses. Used as monotherapy in early disease (mild symptomatic effect, and some evidence of a modest disease-course-modifying/neuroprotective effect, though this remains debated) or as a levodopa adjunct to reduce “wearing-off.”

COMT inhibitors (entacapone, tolcapone): block catechol-O-methyltransferase, an enzyme that degrades levodopa peripherally (competing with the decarboxylation pathway already blocked by carbidopa) — used specifically as levodopa adjuncts (never as monotherapy, since they have no independent antiparkinsonian effect) to extend levodopa’s plasma half-life and smooth out motor fluctuations in patients already experiencing “wearing-off.” Tolcapone carries a specific hepatotoxicity risk requiring liver function monitoring, distinguishing it from entacapone.

Anticholinergics (trihexyphenidyl, benztropine): block muscarinic receptors, reducing the relatively excessive cholinergic striatal tone described above — particularly effective for tremor specifically (less effect on bradykinesia/rigidity than the dopaminergic agents), and more useful in younger patients (better tolerance of anticholinergic adverse effects) or for drug-induced parkinsonism (see below) than as routine therapy in typical, older-onset Parkinson’s disease, where anticholinergic adverse effects (confusion, memory impairment, urinary retention, blurred vision) are poorly tolerated.

Amantadine: mechanism is multifactorial and not fully settled — increases dopamine release, blocks dopamine reuptake, and has NMDA glutamate receptor antagonist activity, this last property also explaining its separate, later-recognized usefulness specifically for levodopa-induced dyskinesias (distinct from its use for parkinsonian symptoms themselves). Modest symptomatic effect, used in early/mild disease or as an adjunct for dyskinesia control.

Adverse Effects

Levodopa: nausea/vomiting and postural hypotension (peripheral dopaminergic effects, reduced but not eliminated by carbidopa/benserazide), psychiatric effects (hallucinations, confusion — particularly in elderly patients or with disease-associated cognitive impairment), motor fluctuations and dyskinesias with chronic use (above).

Dopamine agonists: similar but generally more pronounced psychiatric/hallucinatory effects than levodopa at equivalent symptomatic benefit, and a distinctive, specifically-examined risk of impulse control disorders (pathological gambling, hypersexuality, compulsive shopping/eating) — thought related to direct stimulation of mesolimbic dopamine receptors involved in reward circuitry, a risk not shared to the same degree by levodopa itself. Ergot agents: valvulopathy/fibrosis (above).

MAO-B inhibitors: generally well tolerated at standard selective doses; insomnia (selegiline’s amphetamine metabolites), and the tyramine reaction risk if selectivity is lost at high dose or with certain drug combinations.

Anticholinergics: the standard antimuscarinic profile — dry mouth, blurred vision, urinary retention, constipation, confusion (particularly problematic in the elderly, where these agents are generally avoided).

Drug-Induced Parkinsonism

A specific, frequently-tested clinical scenario distinct from idiopathic Parkinson’s disease: typical antipsychotics (D2 receptor blockers — see Antipsychotic and Antimanic Drugs) are the classic cause, producing parkinsonian features by pharmacologically reproducing the same dopamine-deficient state (blocking D2 receptors rather than losing the neurons that supply dopamine, but the net striatal effect on dopaminergic signalling is functionally similar). Management is to reduce/switch the offending drug where possible; anticholinergics are useful here specifically (correcting the relative cholinergic excess directly), whereas levodopa is generally ineffective (there’s no shortage of dopamine to replace — the receptors are simply blocked).

Clinical Relevance

The dopamine/acetylcholine balance framework is what makes this topic’s drug list organized rather than arbitrary: every dopamine-boosting strategy (precursor, agonist, reduced breakdown by two independent enzymes) addresses one side of the imbalance, while anticholinergics address the other side directly — and this same framework immediately explains why anticholinergics, not levodopa, are the rational choice in drug-induced parkinsonism, where the problem is excess receptor blockade rather than a dopamine shortfall to replace.

• Levodopa’s path from oral dose to striatal dopamine, marking where carbidopa/benserazide and COMT inhibitors each block peripheral breakdown.
• Dopamine/acetylcholine balance in the striatum, with each drug class mapped to which side of the balance it corrects.

Short Essays (1)

Essays (1)

Short Answers (8)

Short Notes (2)

Multiple Choice Questions (1)